An important experiment going forward, due to its therapeutic implications, is to establish whether this microtubule association is observed in cells expressing high endogenous levels of LRRK2 and under conditions that would favor this interaction: LRRK2 carrying PD-linked mutations that enhance microtubule association and treatment with a LRRK2-specific Type I inhibitor. The gene discussed is LRRK2; the disease is Parkinson disease.